Search for other papers by Kirsten E. Stewart in
Google Scholar
PubMed
Search for other papers by Mark W.J. Strachan in
Google Scholar
PubMed
Search for other papers by Devraj Srinivasan in
Google Scholar
PubMed
Search for other papers by Morna MacNeill in
Google Scholar
PubMed
Search for other papers by Lucy Wall in
Google Scholar
PubMed
Search for other papers by Iain J. Nixon in
Google Scholar
PubMed
). What Does This Case Report Add? This case illustrates a patient with locally advanced DTC treated with tyrosine kinase inhibitor (TKI) therapy, which markedly reduced tumour volume and allowed subsequent successful surgical resection without
Search for other papers by Satoshi Koyama in
Google Scholar
PubMed
Search for other papers by Naritomo Miyake in
Google Scholar
PubMed
Search for other papers by Kazunori Fujiwara in
Google Scholar
PubMed
Search for other papers by Tsuyoshi Morisaki in
Google Scholar
PubMed
Search for other papers by Takahiro Fukuhara in
Google Scholar
PubMed
Center for Head and Neck Surgery, Kusatsu General Hospital, Kusatsu, Japan
Search for other papers by Hiroya Kitano in
Google Scholar
PubMed
Search for other papers by Hiromi Takeuchi in
Google Scholar
PubMed
strategies are required to improve the prognosis. Lenvatinib is an oral tyrosine kinase inhibitor targeting VEGFR1–3, FGFR1–4, RET, KIT, and PDGFRβ [ 6 - 8 ]. It was associated with a marked improvement in progression-free survival in patients with
Search for other papers by Laura Ximena Kattah Martinez in
Google Scholar
PubMed
Search for other papers by Lisseth Fernanda Marín Carrillo in
Google Scholar
PubMed
Search for other papers by Leonardo Rojas Melo in
Google Scholar
PubMed
What Is Known About This Topic? Several side effects have been described with the use of tyrosine kinase inhibitors like sorafenib. Nonetheless, only 9 cases of pancreatitis related to sorafenib treatment have been described, all of them
Institute of Pathology, University Hospital Halle (Saale), Halle (Saale), Germany
Search for other papers by Markus Eszlinger in
Google Scholar
PubMed
Search for other papers by Paul Stewardson in
Google Scholar
PubMed
Search for other papers by John B McIntyre in
Google Scholar
PubMed
Search for other papers by Adrian Box in
Google Scholar
PubMed
Search for other papers by Moosa Khalil in
Google Scholar
PubMed
Search for other papers by Martin Hyrcza in
Google Scholar
PubMed
Search for other papers by Konstantin Koro in
Google Scholar
PubMed
Search for other papers by Dean Ruether in
Google Scholar
PubMed
Search for other papers by Jiahui Wu in
Google Scholar
PubMed
Search for other papers by Ralf Paschke in
Google Scholar
PubMed
Introduction The neurotrophic tyrosine kinase receptor (NTRK) inhibitors, larotrectinib and entrectinib, were approved by the United States Food & Drug Administration (FDA) for the treatment of NTRK fusion-positive solid tumors that are
Department of Endocrinology and Nephrology, Division of Nephrology, University Clinic Leipzig, Leipzig, Germany
Search for other papers by Luisa Paschke in
Google Scholar
PubMed
Search for other papers by Thomas Lincke in
Google Scholar
PubMed
Search for other papers by Katja Sibylle Mühlberg in
Google Scholar
PubMed
Search for other papers by Wolfram J. Jabs in
Google Scholar
PubMed
Search for other papers by Tom H. Lindner in
Google Scholar
PubMed
Search for other papers by Ralf Paschke in
Google Scholar
PubMed
treatment with lenvatinib and no concerning co-medications were reported. What Does This Case Report Add? We report two severe AEs of anti-VEGF tyrosine kinase inhibitor treatment which were not reported in the phase III trials. Our case
Endocrinology Department, Instituto Português de Oncologia de Lisboa Francisco Gentil, Lisbon, Portugal
Search for other papers by Francisco Sousa Santos in
Google Scholar
PubMed
Search for other papers by Rita Joana Santos in
Google Scholar
PubMed
Faculty of Medical Sciences of Lisbon, Lisbon, Portugal
Search for other papers by Valeriano Leite in
Google Scholar
PubMed
a part in the pathogenesis of thyroid cancer and these represent potential treatment targets [ 6 ]. As such, several multitargeted tyrosine kinase inhibitors (TKIs) have been investigated for the treatment of RAI-refractory thyroid cancer with the
Search for other papers by Simone De Leo in
Google Scholar
PubMed
Department of Pathophysiology and Transplantation, Università degli Studi di Milano, Milan, Italy
Search for other papers by Carla Colombo in
Google Scholar
PubMed
Search for other papers by Marta Di Stefano in
Google Scholar
PubMed
Search for other papers by Antonella Dubini in
Google Scholar
PubMed
Search for other papers by Silvia Cozzi in
Google Scholar
PubMed
Department of Clinical Sciences and Community Health, Università degli Studi di Milano, Milan, Italy
Search for other papers by Luca Persani in
Google Scholar
PubMed
Department of Pathophysiology and Transplantation, Università degli Studi di Milano, Milan, Italy
Search for other papers by Laura Fugazzola in
Google Scholar
PubMed
biological characteristics of this tumor, which has a relatively low growth rate and is poorly symptomatic. Nevertheless, patients experience a relevant weight decrease when treatment with a tyrosine kinase inhibitor (TKI) is started, such as lenvatinib
Internal Medicine, Erasmus MC, University Medical Center Rotterdam
Search for other papers by Sita Virakul in
Google Scholar
PubMed
Search for other papers by Leendert van Steensel in
Google Scholar
PubMed
Search for other papers by Virgil A.S.H. Dalm in
Google Scholar
PubMed
Department of Ophthalmology, Geneva University Hospitals, Geneva, Switzerland
Search for other papers by Dion Paridaens in
Google Scholar
PubMed
Internal Medicine, Erasmus MC, University Medical Center Rotterdam
Rotterdam Eye Hospital, Rotterdam, The Netherlands
Search for other papers by P. Martin van Hagen in
Google Scholar
PubMed
Search for other papers by Willem A. Dik in
Google Scholar
PubMed
fibroblast functions In recent years numerous novel, targeted therapies have been introduced in clinical practice, like the biologicals and tyrosine kinase inhibitors (TKIs). Therapeutic strategies that target specific cytokines, growth factors or
Department of Surgery, Ito Hospital, Shibuya-ku, Tokyo, Japan
Search for other papers by Haruhiko Yamazaki in
Google Scholar
PubMed
Search for other papers by Kiminori Sugino in
Google Scholar
PubMed
Search for other papers by Ryohei Katoh in
Google Scholar
PubMed
Search for other papers by Kenichi Matsuzu in
Google Scholar
PubMed
Search for other papers by Wataru Kitagawa in
Google Scholar
PubMed
Search for other papers by Mitsuji Nagahama in
Google Scholar
PubMed
Search for other papers by Aya Saito in
Google Scholar
PubMed
Search for other papers by Koichi Ito in
Google Scholar
PubMed
RAI. However, some FTCs become refractory to RAI. Multi-tyrosine kinase inhibitors such as sorafenib and lenvatinib are utilized for treating RAI-refractory FTCs ( 8 , 9 ). Numerous guidelines regarding differentiated thyroid carcinoma have been
Search for other papers by Roberto Fiore in
Google Scholar
PubMed
Search for other papers by Stefano La Rosa in
Google Scholar
PubMed
Search for other papers by Silvia Uccella in
Google Scholar
PubMed
Search for other papers by Deborah Marchiori in
Google Scholar
PubMed
Search for other papers by Peter A Kopp in
Google Scholar
PubMed
hypothyroidism was first induced by systemic therapy with checkpoint inhibitors, and then further complicated by consumptive hypothyroidism. In this context, it is worthwhile mentioning that D3 activity can be increased by therapy with tyrosine kinase inhibitors